Back to Results

Cerus Corporation (CERS)

Featured in High-Growth Small-Cap Stocks

Cerus Corporation (NASDAQ-CERS) is a healthcare company whose common stock trades on NASDAQ. The Cerus Corporation security is described here as common equity, reflecting an ownership interest in the issuer rather than a fund, debt instrument, or other listed product. The company’s business is centered on blood safety technologies used in the processing of donated blood components. Its work relates to reducing contamination risk in transfusion-related materials and supporting pathogen reduction across selected blood products. As a healthcare equipment and supplies name, Cerus is associated with specialized medical technology rather than broad consumer health products.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-CERS
$1.97
-7.4% Downside
Fair
$5.13
140.6% Upside
Bargain
Fair
0.0%
February 25, 2027
5.7x
1.9x
428.1 M
448.7 M
13.3%
96.9%
-3.7
-6.8%
Valuation • Fair Value

Cerus Corporation (NASDAQ-CERS) Fair Value by Valuation Model

Review the available estimates for Cerus Corporation (NASDAQ-CERS), including DCF Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$1.97

Estimated downside of 7.4% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$2.10

Discounted cash flow valuation reference.

EPV Fair Value

$1.27

Earnings power value estimate.

Comps Fair Value

$1.96

Comparable-company valuation reference.

Analyst Price Target

$5.13

Analysts imply upside of 140.6%.

How to read these valuation models

Use the 6 available valuation references for Cerus Corporation (NASDAQ-CERS) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Cerus Corporation (NASDAQ-CERS)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

226.6 M

Current operating scale indicator.

Revenue Forecast

242.3 M

Forward revenue estimate.

EBITDA

-748 K

Current operating profitability reference.

EBITDA Forecast

18.095 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Cerus Corporation (NASDAQ-CERS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Cerus Corporation (NASDAQ-CERS)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.61

No elevated caution signal from this screen.

Altman Z-Score

-3.7

Lower score that deserves closer risk review.

FCF / Net Income

-6.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Cerus Corporation (NASDAQ-CERS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Cerus Corporation (NASDAQ-CERS)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

February 25, 2027

Days to Earnings

111

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Cerus Corporation (NASDAQ-CERS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Cerus Corporation (NASDAQ-CERS) Stock Forecast & Technical Outlook

Review Cerus Corporation (NASDAQ-CERS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Cerus Corporation (NASDAQ-CERS) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Cerus Corporation (NASDAQ-CERS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Cerus Corporation (NASDAQ-CERS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Cerus Corporation (NASDAQ-CERS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Cerus Corporation (NASDAQ-CERS) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Cerus Corporation (NASDAQ-CERS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Cerus Corporation (NASDAQ-CERS) has a Strong Buy consensus, with 4 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 4
Hold 0
Sell 0
FAQ • Fast Investor Answers

Cerus Corporation (NASDAQ-CERS) Stock FAQ

Data-supported answers about Cerus Corporation (NASDAQ-CERS), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.97
Estimated downside 7.4%
Valuation Rating
Overvalued
Estimated downside of 7.4%
Analyst Target
$5.13
Implied upside 140.6%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Cerus Corporation (NASDAQ-CERS) is $1.97. This implies an estimated downside of 7.4% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 7.4% versus the current market price.

The available analyst price target for Cerus Corporation (NASDAQ-CERS) is $5.13. The analyst target implies estimated upside of 140.6%.

The current financial health read for Cerus Corporation (NASDAQ-CERS) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Cerus Corporation (NASDAQ-CERS) is February 25, 2027.

The latest available data indicates no current dividend yield for Cerus Corporation (NASDAQ-CERS).

The current market capitalization listed for Cerus Corporation is 428.1 M.

The current enterprise value listed for Cerus Corporation is 448.7 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Cerus Corporation is NASDAQ-CERS, and the stock is listed on NASDAQ.

Cerus Corporation (NASDAQ-CERS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Cerus Corporation is 13.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Cerus Corporation is 96.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 196.7 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 162.4 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 128.3 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 127.6 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 64.704 B
BDX NYSE Becton Dickinson and Co Fair Value Fair Market Cap 58.168 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 57.971 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 52.86 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 52.302 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Fair Market Cap 37.867 B
ALC NYSE Alcon AG Fair Value Fair Market Cap 37.14 B
RMD NYSE ResMed Inc Fair Value Fair Market Cap 33.661 B
DXCM NASDAQ DexCom Inc Fair Value Undervalued Market Cap 31.503 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Fair Market Cap 30.181 B
STE NYSE STERIS plc Fair Value Fair Market Cap 24.777 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Fair Market Cap 20.222 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 14.84 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 13.319 B
BAX NYSE Baxter International Inc Fair Value Fair Market Cap 13.27 B
GKOS NYSE Glaukos Corp Fair Value Overvalued Market Cap 13.016 B